CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lunai Bioworks Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lunai Bioworks Inc
2080 Century Park East,, Suite 906,
Phone: (212) 763-0184p:212 763-0184 LOS ANGELES, CA  90067  United States Ticker: RENBRENB
Business Summary
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20256/30/2024YesYes--Yes

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director DavidWeinstein 64 10/14/2024 10/14/2024
Chief Financial Officer NathenFuentes 42 1/6/2025 1/6/2025
Independent Director Douglas W.Calder 56 10/14/2024 10/14/2024
Independent Director Mark A.Collins 10/14/2024 10/14/2024
Independent Director James A.Mcnulty 72 10/14/2024 10/14/2024

Subsidiaries
Business Name Address City State/Province Country
BioSymetrics, Inc. 315 Main St Huntington NY United States

Business Names
Business Name
BioSymetrics, Inc.
DDRT
ENOB
8 additional Business Names available in full report.

General Information
Number of Employees: 25 (As of 6/30/2024)
Outstanding Shares: 230,928,963 (As of 7/15/2025)
Shareholders: 197
Stock Exchange: NASD
Federal Tax Id: 452559340
Fax Number: (845) 818-3588


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!